KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EPS (Basic): 2009-2025

Historic EPS (Basic) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $4.24.

  • Vertex Pharmaceuticals' EPS (Basic) rose 4.69% to $4.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $14.31, marking a year-over-year increase of 873.51%. This contributed to the annual value of -$2.08 for FY2024, which is 114.80% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' EPS (Basic) stood at $4.24, which was up 5.47% from $4.02 recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' EPS (Basic) peaked at $4.26 during Q1 2024, and registered a low of -$13.92 during Q2 2024.
  • Its 3-year average for EPS (Basic) is $2.07, with a median of $3.76 in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' EPS (Basic) surged by 1,119.23% in 2022 and then slumped by 492.11% in 2024.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' EPS (Basic) stood at $3.01 in 2021, then increased by 5.98% to $3.19 in 2022, then increased by 17.87% to $3.76 in 2023, then fell by 6.12% to $3.53 in 2024, then rose by 4.69% to $4.24 in 2025.
  • Its last three reported values are $4.24 in Q3 2025, $4.02 for Q2 2025, and $2.52 during Q1 2025.